肿瘤防治研究2025，Vol.52Issue(12)：980-987,8.DOI:10.3971/j.issn.1000-8578.2025.25.0668
BCL-2抑制剂在急性髓系白血病中的应用及展望
Application and Prospects of BCL-2 Inhibitors in Acute Myeloid Leukemia
摘要
Abstract
Research into the molecular biology of acute myeloid leukemia(AML)has facilitated the identification of therapeutic targets and the development of corresponding molecularly targeted drugs.The advent of the BCL-2 inhibitor venetoclax(VEN)concludes 50 years of stagnant clinical progress in AML and ushered in a new era of targeted therapy for this disease.Treatment regimens based on VEN had been applied to older patients and individuals unsuitable for intensive chemotherapy initially,but extensive studies on intensive and non-intensive clinical regimens incorporating VEN have confirmed its potential applicability to a broader patient demographic.This article systematically reviews the mechanism of action,resistance mechanisms,and optimization strategies of VEN in the context of AML.关键词
B细胞淋巴瘤-2/维奈克拉/急性髓系白血病/治疗策略Key words
BCL-2/Venetoclax/Acute myeloid leukemia/Therapeutic strategy分类
医药卫生引用本文复制引用
姚振,李正,薛胜利..BCL-2抑制剂在急性髓系白血病中的应用及展望[J].肿瘤防治研究,2025,52(12):980-987,8.基金项目
National Natural Science Foundation of China(Nos.82470224,82270165) （Nos.82470224,82270165）
Boxi Clinical Research Project(No.BXLC008) （No.BXLC008）
Boxi Leading Talent Program(No.02622) 国家自然科学基金(82470224,82270165) （No.02622）
博习临床研究项目(BXLC008) （BXLC008）
博习领军人才计划(02622) （02622）
